Search Results
How to Better Diagnose Patients With High-Risk Myeloma | Martin Kaiser, MD | ASH 2022
OPTIMUM MUK Nine Trial | Martin Kaiser, MD | ASH 2022
OPTIMUM/MUK nine clinical trial with Dr Martin Kaiser
High-Risk Disease | High Impact Topic (HIT)
KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
GRIFFIN Trial Update - DVRd vs VRd in Newly Diagnosed Myeloma | Peter Voorhees, MD | ASH 2021
Improving the identification of patients with high-risk multiple myeloma
Management of High-Risk Myeloma
IDE-CEL vs Standard Regimens for High-Risk Multiple Myeloma: KARMMA-3 Analysis | ASCO 2023
Special approaches to myeloma patients with high-risk cytogenetics
Optimizing management of the high-risk myeloma patient
The importance of genetic testing in high-risk multiple myeloma & targeted therapy
